article thumbnail

Parallel import of medicinal products: regulatory update

European Pharmaceutical Review

This is due to the regulatory requirements imposed on parallel imported medicinal products in various Member States, the fulfilment of which often requires repackaging. Repackaging a medicinal product… means that the trademark is reapplied by an entity other than the trademark proprietor.”

article thumbnail

Can technology help diversify clinical trials?

pharmaphorum

Liam Johnstone has six years of toxicology experience working across regulators in the UK, developing expertise in medicine, consumer product and agrochemical safety whilst working at the MHRA, OPSS and HSE, respectively. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts

STAT

The big blow to Sunovion, he said, was the loss of patent protection for Latuda, its best-selling schizophrenia drug, which led to competition from cheaper generic medicines. “The severance package that I received from Sunovion was very generous and will tide me over until December,” he said. Absolutely.”

Vaccines 135
article thumbnail

Adderall XR (amphetamine-dextroamphetamine ER) alternatives: What can I take instead of Adderall XR?

The Checkup by Singlecare

It is also available as a generic medicine called amphetamine- dextroamphetamine ER. The packaging can also be convenient as the tablets come in portable blister packs for those on the go. Adzenys XR shares similar common side effects as Adderall XR and is taken once a day.

Dosage 52
article thumbnail

What happened to all the antibiotics?

pharmaphorum

These include allowing the exceptional supply of certain medicines that may not be authorised in a particular Member State or granting full or partial exemptions to certain labelling and packaging requirements to address severe problems in respect of the availability of some medicines.”

article thumbnail

Why are clinical trials struggling with diversity?

pharmaphorum

Liam Johnstone has six years of toxicology experience working across regulators in the UK, developing expertise in medicine, consumer product and agrochemical safety whilst working at the MHRA, OPSS and HSE, respectively. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines.

Packaging 143
article thumbnail

Halting Europe’s essential medicines manufacturing exodus

European Pharmaceutical Review

The recent update to the EC Urban Waste Directive, part of the environment package ‘Towards Zero Pollution,’ 4 has a disproportionate producer responsibility principle that will incur considerable extra costs. This is likely to make some essential medicines and APIs economically unsustainable to manufacture.